- Research
- Open Access
Evidence-based genomic diagnosis characterized chromosomal and cryptic imbalances in 30 elderly patients with myelodysplastic syndrome and acute myeloid leukemia
https://doi.org/10.1186/1755-8166-4-3
© Bajaj et al; licensee BioMed Central Ltd. 2011
- Received: 2 January 2011
- Accepted: 20 January 2011
- Published: 20 January 2011
Abstract
Background
To evaluate the clinical validity of genome-wide oligonucleotide array comparative genomic hybridization (aCGH) for detecting somatic abnormalities, we have applied this genomic analysis to 30 cases (13 MDS and 17 AML) with clonal chromosomal abnormalities detected in more than 50% of analyzed metaphase cells.
Results
The aCGH detected all numerical chromosomal gains and losses from the mainline clones and 113 copy number alterations (CNAs) ranging from 0.257 to 102.519 megabases (Mb). Clinically significant recurrent deletions of 5q (involving the RPS14 gene), 12p12.3 (ETV6 gene), 17p13 (TP53 gene), 17q11.2 (NF1 gene) and 20q, double minutes containing the MYC gene and segmental amplification involving the MLL gene were further characterized with defined breakpoints and gene contents. Genomic features of microdeletions at 17q11.2 were confirmed by FISH using targeted BAC clones. The aCGH also defined break points in a derivative chromosome 6, der(6)t(3;6)(q21.3;p22.2), and an isodicentric X chromosome. However, chromosomally observed sideline clonal abnormalities in five cases were not detected by aCGH.
Conclusions
Our data indicated that an integrated cytogenomic analysis will be a better diagnostic scheme to delineate genomic contents of chromosomal and cryptic abnormalities in patients with MDS and AML. An evidence-based approach to interpret somatic genomic findings was proposed.
Keywords
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Patient
- Genomic Aberration
- Acute Myeloid Leukemia Case
- aCGH Analysis
Introduction
The identification of recurrent chromosomal abnormalities in various leukemias and the understanding of molecular defects and pathogenic mechanisms underlying these abnormalities have made cytogenetic analysis valuable in providing diagnostic and prognostic parameters for disease stratification and treatment evaluation [1]. With an average resolution of 6-10 megabases (Mb) on a 300-500 G-band level, conventional karyotyping has been the current standard for screening chromosomal abnormalities on metaphases from direct and cultured bone marrow (BM) and leukemic blood (LB) cells. This approach requires mitotic active cells and frequently encounters difficulties due to the low mitotic index and poor chromosome morphology of leukemic cells. Fluorescence in situ hybridization (FISH) tests using targeted probes to detect gene/locus-specific rearrangements have enhanced the analytical resolution to 300-800 kilobases (Kb) and extended conventional metaphase analysis into interphase cells. Current cytogenetic analysis for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) involves cell-based conventional chromosomal analysis and FISH assays using a panel of targeted probes [2, 3]. We have previously validated a DNA-based genome-wide oligonucleotide array comparative genomic hybridization (aCGH) for clinical diagnosis of constitutional chromosomal abnormalities and genomic disorders in pediatric patients with mental retardation and developmental delay [4]. The clinical utility of this aCGH based on Agilent's 44K design (CGH4410B) has demonstrated an average analytical resolution of 300-500 Kb and an improved abnormal detection rate from 5-7% by conventional chromosome and FISH analyses to 12% by aCGH [5]. Evidence-based guidelines to interpret genomic findings in the pediatric patients have been proposed [6, 7]. Recently, genome-wide analyses using BAC-clone aCGH, oligonucleotide aCGH and SNP array have been applied in a research or an exploratory setting to profile the genomic alterations in patients with MDS and AML [8–15]. To evaluate the diagnostic value of aCGH in detecting somatic chromosomal and segmental copy number alterations (CNAs), we have performed aCGH analysis on 30 MDS and AML cases with different clonal abnormalities. The results further characterized the genomic complexity of recurrent chromosomal deletions, duplications, amplifications and cryptic aberrations. Despite its inherent limitation in detecting recurrent balanced reciprocal translocations and low level secondary clonal abnormalities, the aCGH analysis provides detailed genomic features of simple and complex chromosomal abnormalities and cryptic aberrations otherwise not detectable by conventional G-band and FISH assays. Integrated chromosome and genomic analyses and evidence-based interpretation should be a standardized cytogenomic procedure for patients with MDS and AML.
Materials and methods
Patient Samples
Recognized chromosomal abnormalities in the 30 patients with MDS and AML
Case# | Age(yr) | Sample | Type | Chromosome/FISH Results* |
---|---|---|---|---|
1 | 71 | BM | AML | 45,XY,del(5)(q11.1q35.1),-11,-12,add(17)(p11.2),i(22)(q10)add(q13),+3mar[13] |
2 | 74 | BM | MDS | 46,X,t(X;3)(p21;p14),del(5)(q21q33)[20] |
3 | 86 | LC | MDS | 50-55,XX,+1,del(5)(q23q34),+9,+11,+13,+14,dup(22)(q11q13),+3mar[cp20] |
4 | 73 | BM | AML | 44,XX,der(5)t(5;17)(q35;q12)del(5)(q14q34),del(7)(p11.2),del(9)(p23p23),-17,-18,t(22;22)(q13.3q11.2)dup(22)(q11.2q12.3)[15] |
5 | 77 | LC | AML | 42,XX,del(5)(q12q33),-7,idic(8)(p12),dic(12:16)(p13;p13.3),-18,-20,-21,+mar[20] |
6 | 68 | BM | AML | 45,XX,t(1;11)(p22;q22),del(2)(p13p23),del(4)(q11.2q13.3),del(5)(q14q33),del(7)(q22q36),-12,del(13)(q14q34)[14] |
7 | 51 | BM | MDS | 46,XX,del(5)(q14q33)[5]/45,idem,dic(17;20)(p11.2;q11.2)[9] |
8 | 53 | BM | MDS | 44,XX,del(4)(q13q28),-5,t(7;9)(q32;p13),del(12)(p11.2p13),der(17)t(5;17)(p11;p11)[18] |
9 | 61 | LC | MDS | 44,XY,-5,der(7)t(7;12)(p22;q13),r(9),der(10)t(5;10)(p13;p15),add(11)(q23),-12,-13,add(21)(p11),+1-2mar[cp14] |
10 | 55 | LC | AML | 46,XY,t(6;6)(p23;q16)[11] |
11 | 63 | LC | AML | 45,XY,-7[19] |
12 | 63 | BM | MDS | 46,XY,der(6)t(3;6)(q21.3;p22.2),del(7)(q21.13q31.33)[16] |
13 | 78 | BM | AML | 46,XX,del(1)(q12),+del(1),der(2)t(2;3)(p21;p21),del(2)(q31q37),add(5)(q35),del(7)(q22q36),trp(11)(q13q25),add(17)(q25),+mar[cp19] |
14 | 63 | LC | AML | 47,XY,+8[20] |
15 | 71 | BM | MDS | 46,XY,t(3;21)(q26;q22),+8[17] |
16 | 93 | LC | AML | 50,X,-Y,+4,+5,+7,+8,+8[cp20] |
17 | 20 | LC | AML | 44,XY,der(8)t(8;17)(p11.2;q11.2),-17,-19,-21,+mar[cp20] |
18 | 88 | BM | MDS | 46,XY,del(9)(q12q31)[20] |
19 | 74 | BM | MDS | 47,XX,del(9)(q13q31),+18,4-50dmin[20] |
20 | 78 | BM | MDS | 47,XY,+11[18] |
21 | 66 | BM | AML | 46,XY,t(11;19)(q23;p13.1)[14]/46,idem,del(9)(q21q32)[6] |
22 | 60 | BM | AML | 50,XX,+der(1)t(1;13)(q10;q10),+6,+8,t(8:16)(q22;p13),t(11;19)(q23;p13.1),+19,+20[20] |
23 | 51 | LC | AML | 47,XX,t(15;17)(q22;q21.1),+mar[20] |
24 | 73 | BM | MDS | 46,XY,der(17)t(9;17)(p21.1;q25.1)[18] |
25 | 63 | BM | AML | 46,XY,del(20)(q11.2)[16] |
26 | 51 | BM | MDS | 46,XX,del(20)(q11.2)[10]/47,XX,+8[7] |
27 | 79 | BM | AML | 47-48,X,idic(X)(q13),+idic(X)[10]/47,idem,+8[3] |
28 | 61 | BM | AML | 45,X,-Y[20] |
29 | 69 | LC | AML | 45,X,-Y[10]/47,XY,+der(1)t(1;19)(p13;p13),t(16;20)(q21;q12)[10] |
30 | 79 | BM | MDS | 45,X,-Y[17]/50,idem,+X,+15,+20,-22,+3mar[4] |
Conventional Karyotyping and FISH Testing
Conventional chromosome analysis was performed on submitted BM and LB specimens using our laboratory's standardized protocols. Routine FISH tests were performed using a MDS/AML panel of commercial probes for the 5q (EGR1 gene at 5q31), 7q (D7S486 at 7q31), 8q (MYC at 8q24) and 20q (D20S108 at 20q12) loci and for the RUNX1T1 (ETO, 8q21.3), ETV6 (TEL, 12p13.2), RUNX1 (AML1, 21q22), MLL (11q23.3), PML (15q22), RARA (17q21.1), CBFB (16q22) genes and other relevant loci (Abbott Molecular, Des Plaines, IL). To confirm significant cryptic genomic aberrations, DNA samples from two BAC clones, RP11-1107G21 (NF1 gene at 17q11.2, chr17:26,415,260-26,627,398, sequence designation per NCBI36/hg18 assembly of the UCSC Human Genome browser http://genome.ucsc.edu/ and RP11-55J8 (RHOT1 gene at 17q11.2, chr17:27,462,203-27,654,151), were purchased from Roswell Park Cancer Institute (Buffalo, NY). The labeling of BAC DNA with fluorescent nucleotides by nick translation, the hybridization and the image analysis were performed as previously described [4, 16].
The aCGH Analysis and Data Analysis
Genomic DNAs were extracted from the residual BM or LB specimens using Puregene Kit by following manufacturer's instruction (Qiagen Inc., Valencia, CA). DNA concentration was measured using a NanoDrop spectrophotometer (ND-1000, Thermo Fisher Scientific Inc., Waltham, MA) and high molecular weight DNA quality was verified by agarose gel electrophoresis. For each aCGH analysis, 2.5 ug of test genomic DNA from the patient and 2.5 ug of control DNA from a sex-matched or -mismatched healthy individual were used following the manufacturer's protocol for the Agilent Human Genome aCGH microarray 44K kit (Agilent Technologies Inc., Santa Clara, CA). This laboratory has validated the aCGH procedure to offer 99% sensitivity and 99% specificity with an average analytical resolution of 300-500 Kb using the log2 ratio from five to seven contiguous probes, and also demonstrated its capacity in detecting 25%, 33% and 50% level of mosaicism [4]. The differential labeling of test and control DNAs, comparative hybridization onto 4x44K Agilent slides, post-hybridization wash, slide scanning, image feature extraction were processed as previously described [4, 16]. Data was analyzed using Agilent's DNA Analytical (version 4.0) with the built-in ADM-2 algorithm set at threshold value of 6, a cut off value of 0.25, and a filter of six probes. All CNAs except the recognized copy number variants from the Database of Genomic Variants http://projects.tcag.ca/variation/ were recorded. The base pair designations from the Agilent 44K array are according to the March 2006 Assembly (NCBI36/hg18) on the UCSC Human Genome browser http://genome.ucsc.edu/. The aCGH finding from each case was compared with the chromosomally detected clonal abnormality to further define the breakpoint and the gene content involved. Raw data from the 30 cases were loaded onto the Nexus5 Software (BioDiscovery, Los Angles) to evaluate the genome-wide distribution and relative frequency of chromosomal and genomic alterations.
Results
Genome-wide incidence map of abnormal findings from the 30 MDS and AML cases. Complied deletions (red) and duplications (green) from all cases are shown in the top panel and from subgroups based on the major chromosomal abnormalities of 5q deletion (n = 9), 7q deletion (n = 3), trisomy 8 (n = 3), 20q deletion (n = 2), loss of Y chromosome (n = 3) and others (n = 10) are shown in the bottom panel.
Size distribution of genomic imbalances
Size | No. of Imbalances | Percentage |
---|---|---|
< 1 Mb | 5 | 3.5 |
1~5 Mb | 30 | 20.8 |
5~10 Mb | 15 | 10.4 |
10~20 Mb | 23 | 16 |
> 20 Mb | 40 | 27.8 |
Chr. Gain/Loss | 31 | 21.5 |
Total | 144 | 100 |
No. Imbalances per case | No. Of Cases | Percentage |
0 | 2 | 6.7 |
1~5 | 19 | 63.3 |
5~10 | 4 | 13.3 |
> 10 | 5 | 16.7 |
Genomic features of chromosomal abnormalities and cryptic alterations. A) Genome and chromosome views and correlated chromosomal rearrangements for case #4 show large deletion in 5q, truncated deletions in 7p, cryptic deletions in 9p23 and 17q11 (arrows), large duplication and deletion in 17q, a loss of a chromosome 18, segmental duplication and deletion in 22q. The 17q12-q21.31 duplication and 17q21.31-q24.1 deletion may be translocated onto the deleted 5q, and the 22q11.21-q12.3 duplication and 22q13.31-qter deletion may be initiated from a 22q/22q translocation. B) Left panel shows a cryptic genomic deletion of 17q11 in case #22 and FISH using probes for the NF1 and RHOT1 genes confirmed the NF1 gene deletion. Middle panel shows a deletion of 17q11.2 including the NF1 and RHOT1 genes in case #5 and a 17q11.2 deletion distal to the NF1 gene in case #13. Right panel shows complex 11q deletion and amplification involving the MLL gene at 11q23.3 in case #1.
Microdeletions of 1.510 to 3.615 Mb encompassing the NF1 gene at 17q11.2 were found in three cases (cases #4, #5 and #22). FISH analysis using BAC clone probes for the NF1 and RHOT1 genes confirmed these deletions (Figure 2B). It was interesting to observe a transition pattern in case #4 with deletions of NF1 alone, NF1 and RHOT1, and RHOT1 alone in 11%, 12.5% and 34% of cells, respectively. In case #13, a deletion involving the RHOT1 gene but not the NF1 gene was noted and confirmed by FISH. These results suggested that the 17q11.2 region may contain hot spots for initiating deletions from either one or both proximal and distal orientations.
The dmin chromosomes observed in case #19 were further defined as a 4.277 Mb amplification of 8q24.13-q24.21 containing genes TRIB1, MYC and CCDC26. From the log2 ratio of 2.53 for this amplified region, it was estimated that there were average four dmin chromosomes in each leukemic cell. Compound deletions, triplications or quadruplications for 11q were noted in cases #1 and #13, which resulted in complex intrachromosomal rearrangements carrying amplified segments of the MLL gene (Figure 2B). The derivative chromosome 6, der(6)t(3;6)(q21.3;p22.2), in case #12 was further defined with breakpoints involving the RAB43 gene at 3q21.3 and the KIAA0319 gene at 6p22.2; and the isodicentric chromosome of Xp in case #27 was resulted from break and fusion distal to the PHKA1 gene at Xq13.1 (Additional file 1, Table S1).
Discussion
Cytogenetics has played a major role in both diagnosis and prognosis in patients with hematological malignancies. The newly revised WHO classification of acute myeloid leukemias categorizes AML into subgroups with recurrent genetic abnormalities, with MDS features, treatment related and "not otherwise specified"; the last one is by far the largest category [1]. Cytogenetics is key components of both the international prognostic scoring (IPSS) and the WHO classification-based prognostic scoring systems (WPSS) for the myelodysplastic syndromes [17, 18]. However, within all categories prognostic variation is observed, likely among others due to low sensitivity of conventional cytogenetics [12]. Our data demonstrated that aCGH can detect chromosomal, segmental and cryptic aberrations in LB and BM cells from MDS and AML patients. As summarized in Table 2, the aCGH detected an average of 4.8 CNAs per case ranging from 0 to 22, of which an approximately 44% were less than 10 Mb and not evident by conventional cytogenetic analysis. It is noteworthy while on one hand some relatively large deletions and duplications (> 10 Mb) were missed or unresolved by conventional chromosomal analysis, on the other hand chromosomally detected sideline clones were missed by aCGH. Therefore, an integrated cytogenomic approach using chromosome analysis, FISH assay and aCGH would definitely improve the analytical resolution and abnormality detection rate for MDS and AML patients.
Integrated cytogenomic workflow and proposed algorithm for interpreting and reporting clinically significant genomic findings.
Representative studies showing evidence for relevant genomic alterations in MDS and AML
Patients | Case# | Methods | ADR* | Significance Genomic Findings | EL* | Refs |
---|---|---|---|---|---|---|
AML with complex karyotype | 60 | 2.8K BAC/PAC aCGH | 100% | Frequent losses of 5q(77%), 17p(55%), 7q(45%), 16q, 18q, 17q, 3p, 12q, 20q, 12p, 18p, 13q, 11q; gains/amplifications of 11q(40%), 8q(38%), 21q, 1p, 9p, 22q, 13q, 6p, 19p | II | 8 |
de novo AML | 100 | 44K oligo-aCGH (Agilent) | 74% | Five smallest overlapping regions of imblances: 5q31.3, 16q23.1, 16q24.2, 17q11.2(NF1), 18p11.2 | I | 9 |
AML with normal karyotype | 26 | 44K oligo-aCGH (Agilent) | 15% | Cryptic losses of 8q24.11, 12p12.3, 1q41, 18q21,32, 12p13.2(ETV6), gain 3p21.3, dmin 8q24.13-q24.21(MYC) | II | 10 |
MDS/AML with normal karyotype | 38 | SNP-chip (Affymetrix) | 49% | CNN-LOH of 1p, 6p, 8q, 13q, 19p, 5q, 12q, 21q, 9p; losses of 17q11.2(NF1), 12p13.31p13.2(ETV6), 2q36.2, 4q24, 9p21.3p21.2(CDKN2A), 3p26.3, 14q21.2, 21q21.2, 8p23.2, 2p23.1; gains of 1q43, 18q21.2, 8q24.13q24.21(MYC) | II | 11 |
Low risk MDS (CD34+ cells) | 44 | 32K BAC tiling array | 82% | Recurring common regions: losses of 2p23.1, 2q33.1-q33.2, 4p14, 5q13.1q13.2, 5q14.3q33, 5q33.3, 6p23, 10q21.3, 14q12, 19p12p13.2, 20q11.21q13.13, 22q13.1q13.2; gains of 7q34, 11q12.2, 11q24.2qter, 17q11.2, 17q12 | II | 12 |
Adult de novo AML | 86 | SNP 6.0 genechip (Affymetrix) | 40% | 12 recurring alterations found from 201 CNAs: losses of 3p14.1(FHIT), 5q31.1(CTNNA1), 7q31.31, 12p12.3(ETV6), 16q22.1(CEFB), 17p13.1(TP53), 17q11.2(NF1), 18p11.31; amplifications of 8q23.2(MYC), 11q23.3(MLL), 19q13.43, 21q22.2(ETS2) | I | 13 |
Pediatric de novo AML | 111 | SNP-chips (Affymetrix) | Low# | Signficant losses of 5p15.33, 7p21.3, 7q36.1, 8q21.3 (RUNX1T1), 9p21.3 (CDKN2A), 9p21.2(TUSC1), 9p22.33(XPA), 11p14.1, 11q23.3(MLL), 12p13.31, 16p13.11(MYH11), 16q22.1(CBFB), 18p11.21; amplifications of 8q24.21(CCDC26), 13q32.1(ABCC4), 19p13.2), 21q22.2(ERG, TMPRSS2), 22q12.3. | I | 14 |
MDS/MPN/AML with abnormal karyotype | 30 | SignatureChipWGBAC (v1.01) | 80% | Cryptic RUNX1 deletions, hidden deletions of 3q26.2(EVI1), 5q22(APC),5q32(TCERG1), 12p13.1(EMP1), 12q21.3(KITLG), 17q11.2(NF1), gains of 12p13.32(CCND2) | II | 15 |
MDS/AML with abnormal karyotype | 30 | 44K oligo-aCGH (Agilent) | 93% | Recurring alterations: losses of 5q(RPS14), 12p12.3(ETV6), 17p13(TP53), 17q11.2(NF1), 20q; gains of 8q24(MYC),11q23.2(MLL). | II | this report |
Basic researches toward the understanding of gene functions and disease-causing mechanisms or case reports with unique clinical and genomic findings could provide level III and IV evidence for reporting genomic alterations. Detailed genomic analyses of the malignant cells in MDS and AML patients is likely to yield specific types or regions of recurrent chromosomal and genomic abnormalities providing further evidence for disease association and allowing identification of to date unknown candidate genes. Eventually, further classification of disease and targeted treatment can potentially result from such knowledge. The 5q deletion is possibly the best understood recurrent chromosomal deletion in myeloid malignancies. Two common deletion regions (CDR) have been identified conferring either a good (CDR1) or a poor (CDR2) prognosis, but usually changes are more complex [19]. All 5q deletions in our 10 cases and in another study of 12 MDS cases with an isolated 5q deletion by Evers C et al. [20] involved the loss of the RPS14 gene at 5q33.1, which support the causal role of RPS14 haploinsufficiency and were specified in the diagnostic reports [21]. Other haploinsufficiency genes or miR-145 and miR146a at 5q could also have causal or modifying effects [22–24], and should also be referred in the report. A der(6)t(3;6)(q21;p22) in a patient with AML at relapse and a t(1;6)(q21;p22) in another patient were reported [25]. We reported here a der(6)t(3;6)(q21.3;p22.2) likely caused by fusion of the RAB43 gene at 3q21.3 and the KIAA0319 gene at 6p22.2. Analysis of additional cases with similar 6p22 translocations could clarify if this is a recurrent primary or secondary rearrangement in AML. Monosomy 7 and 7q deletions portend a particularly poor prognosis in myeloid malignancies. The candidate genes within the recurrent 7q deletion are still under investigation and a recent study suggested that the SAMD9, SAMD9L and Miki (LOC253012) as the candidate genes for 7q21.3 [26]. Two out of the three cases with 7q deletions in our patients had the 7q21.3 deletion. As reported in the literature [16, 27, 28] and also shown from our cases #1, #13, # 19 and #23, genomic analysis has been used effectively to define dmin chromosomes of 8q24 and complex 11q rearrangements with or without the MLL gene amplification in simple or complex karyotype. The presence of cytogenetic unresolved marker chromosome in our case #23 and the reported hidden abnormalities associated with t(15;17) justified further genomic analysis for this obvious balanced rearrangements [29, 30]. Microdeletions at 17q11.2 involving the NF1 gene are considered to be recurrent cryptic alterations in three of our cases (#4, #5 and #22) and also documented in several reports [9, 11–13, 31]. The presence of clustered flanking repetitive sequences of the NF1 locus is a likely explanation for recurrence of both constitutional and the somatic deletions [32]; further characterization of the noted transition pattern for the somatic 17q11.2 deletion could lead to better understanding of its mutagenesis mechanism.
In conclusion, our current diagnostic application of aCGH and accumulated evidence from previous studies support an integrated cytogenomic approach with evidence-based interpretation in MDS and AML patients with 1) > 20% blast cells with or without clonal chromosomal abnormality, 2) with complex chromosomal abnormalities, and 3) with simple and balanced rearrangements or a normal karyotyope but suspected cryptic abnormalities. This cytogenomic approach may not only provide a better diagnostic scheme to delineate breakpoints and gene contents of chromosomal and cryptic abnormalities in patients with MDS and AML, but hopefully allow identification of disease-causing or modifying candidate genes, and eventually lead to improved prognostification and treatment of patients with MDS and AML.
Declarations
Acknowledgements
Yale Center of Excellent for Molecular Hematology (YCEMH-P30) pilot grant to Peining Li supported part of this work. We would like to thank Joan Samuelson and Fang Lin for their technical support, and also extend our appreciation to the patients who participated in this study.
Authors’ Affiliations
References
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Eds): WHO classification of tumors of haematopoietic and lymphoid tissues International Agency for Research on Cancer (IARC); 2008.Google Scholar
- Lowenberg B, Downing JR, Burnett A: Acute myeloid leukemia. New England J Med 1999, 341: 1051–1061. 10.1056/NEJM199909303411407View ArticleGoogle Scholar
- Vance GH, Kim H, Hicks GA, Cherry AM, Higgins R, Hulshizer RL, Tallman MS, Fernandex HF, Dewald GW: Utility of interphase FISH to stratify patient into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). Leukmia Res 2007, 31: 605–609. 10.1016/j.leukres.2006.07.026View ArticleGoogle Scholar
- Xiang B, Li A, Valentin D, Novak N, Zhao HY, Li P: Analytical and clinical validity of whole genome oligonucleotide array comparative genomic hybridization for pediatric patients with mental retardation and developmental delay. Am J Med Genet 2008, 146A: 1942–1954. 10.1002/ajmg.a.32411PubMedView ArticleGoogle Scholar
- Xiang B, Zhu H, Shen Y, Nasir R, Sobeih M, Miller D, Lu K, Hu X, Andersson H, Narumanchi TC, Wang Y, Martinez JE, Wu BL, Li P, Li M, Chen TJ, Fan YS: Genome-wide oligonucleotide Array CGH for etiological diagnosis of mental retardation: A multi-center experience on 1,499 clinical cases. J Mol Diagn 2010, 12: 204–212. 10.2353/jmoldx.2010.090115PubMed CentralPubMedView ArticleGoogle Scholar
- Toriello HV, Goldenberg P: Evidence-based medicine and practice guidelines: application to genetics. Am J Med Genet 2009, 151C: 235–240. 10.1002/ajmg.c.30222PubMedView ArticleGoogle Scholar
- Paciorkowski AR, Fang M: Chromosomal microarray interpretation: what is a child neurologist to do? Ped Neurol 2009, 41: 392–398. 10.1016/j.pediatrneurol.2009.05.003View ArticleGoogle Scholar
- Rücker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Fröhling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H: Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006, 24: 3887–3894.PubMedView ArticleGoogle Scholar
- Suela J, Alvarez S, Cifuenes F, Largo C, Ferreira BI, Blesa D, Ardan M, Garcia R, Marquea JA, Odero MD, Calasanz MJ, Cigudosa JC: DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 2007, 21: 1124–1231. 10.1038/sj.leu.2404653Google Scholar
- Tyybäkinoja A, Elonen E, Piippo K, Knuutila S: Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia 2007, 21: 571–574.PubMedView ArticleGoogle Scholar
- Akagi T, Ogawa S, Dugas M, Kawamata N, Yamamoto G, Nannya Y, Sanada M, Miller CW, Yung A, Schnittger S, Haferlach T, Haferlach C, Koeffler HP: Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 2009, 94: 213–223. 10.3324/haematol.13024PubMed CentralPubMedView ArticleGoogle Scholar
- Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A, Spinelli JJ, Eaves CJ, Eaves AC, Horsman DE, Lam WL, Karsan A: High-resolution whole genome tiling path array CGH analysis of CD34+cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2009, 112: 3412–3424. 10.1182/blood-2007-11-122028View ArticleGoogle Scholar
- Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J, Heath S, Westervelt P, Watson MA, Tomasson MH, Nagarajan R, O'Gara BP, Bloomfield CD, Mrózek K, Selzer RR, Richmond TA, Kitzman J, Geoghegan J, Eis PS, Maupin R, Fulton RS, McLellan M, Wilson RK, Mardis ER, Link DC, Graubert TA, DiPersio JF, Ley TJ: Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci USA 2009, 106: 12950–12955. 10.1073/pnas.0903091106PubMed CentralPubMedView ArticleGoogle Scholar
- Radtke I, Mullighan CG, Ishii M, Su X, Cheng J, Ma J, Ganti R, Cai Z, Goorha S, Pounds SB, Cao X, Obert C, Armstrong J, Zhang J, Song G, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff SA, Downing JR: Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci USA 2009, 106: 12944–12949. 10.1073/pnas.0903142106PubMed CentralPubMedView ArticleGoogle Scholar
- Slovak ML, Smith DD, Bedell V, Hsu YH, O'Donnell M, Forman SJ, Gaal K, McDaniel L, Schultz R, Ballif BC, Shaffer LG: Assessing karyotype precison by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. Mol Cytogenet 2010, 3: 23. 10.1186/1755-8166-3-23PubMed CentralPubMedView ArticleGoogle Scholar
- Kamath A, Tara H, Xiang B, Bajaj R, He W, Li P: Double minute MYC amplification and deletion of MTAP, CDKN2A, CDKN2B and ELAVL2 in a patient with acute myeloid leukemia characterized by oligonucleotide-array comparative genomic hybridization. Cancer Genet Cytogenet 2008, 183: 117–120. 10.1016/j.cancergencyto.2008.02.011PubMedView ArticleGoogle Scholar
- Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89: 2079–2088.PubMedGoogle Scholar
- Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25: 3503–3510. 10.1200/JCO.2006.08.5696PubMedView ArticleGoogle Scholar
- Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A: Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer Genet Cytogenet 2008, 187: 101–111. 10.1016/j.cancergencyto.2008.08.002PubMedView ArticleGoogle Scholar
- Evers C, Beier M, Hildebrandt B, Servan K, Drechsler M, Germing U, Yoyer HD, Royer-Pokora B: Molcular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chr Cancer 2007, 46: 1119–1128. 10.1002/gcc.20498View ArticleGoogle Scholar
- Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR: Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008, 451: 335–339. 10.1038/nature06494PubMed CentralPubMedView ArticleGoogle Scholar
- Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, Frater JL, Walshauser MA, Martin MG, Kasai Y, Walter MJ: Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One 2009,4(2):e4583. 10.1371/journal.pone.0004583PubMed CentralPubMedView ArticleGoogle Scholar
- Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A: Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010, 16: 49–58. 10.1038/nm.2054PubMedView ArticleGoogle Scholar
- Starczynowski DT, Karsan A: Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle 2010, 9: 855–856. 10.4161/cc.9.5.11156PubMedView ArticleGoogle Scholar
- Tchinda J, Dijkhuizen T, Vlies PvP, Kok K, Horst J: Translocations involving 6p22 in acute myeloid leukaemia at relapse: breakpoint characterization using microarray-based comparative genomic hybridization. Br J Haematol 2004, 126: 495–500. 10.1111/j.1365-2141.2004.05082.xPubMedView ArticleGoogle Scholar
- Asou H, Matsui H, Ozaki Y, Nagamachi A, Nakamura M, Aki D, Inaba T: Identification of a common microdeletion cluster in 7q21.3 subband among patients with myeloid leukemia and myelodysplastic syndrome. Biochem Biophys Res Commun 2009, 383: 245–251. 10.1016/j.bbrc.2009.04.004PubMedView ArticleGoogle Scholar
- Tyybäkinoja A, Saarinen-Pihkala U, Elonen E, Knuutila S: Amplified, lost, and fused genes in 11q23–25 amplicon in acute myeloid leukemia, an array-CGH study. Genes Chr Cancer 2006, 45: 257–264.View ArticleGoogle Scholar
- Zatkova A, Merk S, Wendehack M, Bilban M, Muzik EM, Muradyan A, Haferlach C, Haferlach T, Wimmer K, Fonatsch C, Ullmann R: AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes. Genes Chr Cancer 2009, 48: 510–520. 10.1002/gcc.20658View ArticleGoogle Scholar
- Dolan M, Peterson B, Hirsch B: Array-based comparative genomic hybridization characterizes a deletion associated with a t(15;17) in acute promyelocytic leukemia. Am J Clin Pathol. 2008, 130: 818–23.Google Scholar
- Akagi T, Shih LY, Kato M, Kawamata N, Yamamoto G, Sanada M, Okamoto R, Miller CW, Liang DC, Ogawa S, Koeffler HP: Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 2009, 113: 1741–1748. 10.1182/blood-2007-12-130260PubMed CentralPubMedView ArticleGoogle Scholar
- Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern T, Schnittger S, Haferlach T: AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 2010, 24: 1065–1069. 10.1038/leu.2010.22PubMedView ArticleGoogle Scholar
- Pasmant E, Sabbagh A, Masliah-Planchon J, Haddad V, Hamel MJ, Laurendeau I, Wolkenstein P, Bieche I, Vidaud M, Vidaud D: Detection and characterization of NF1 microdeletions by custom high resolution array CGH. J Mol Diagn 2009, 11: 524–529. 10.2353/jmoldx.2009.090064PubMed CentralPubMedView ArticleGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.